1
|
Xhaard A, Bouton M, Delugin L, Giraud C, Guyon A, Giroux-Lathuile C, Hajjout K, Nicolas P, Peyrard T, Ratie V, Boisnard A, Capelle L, Godin S, Traineau R, Yacoub-Agha I, Leprêtre AC. [Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S78-S83. [PMID: 37055307 DOI: 10.1016/j.bulcan.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 03/07/2023] [Accepted: 03/08/2023] [Indexed: 04/15/2023]
Abstract
The French High Authority of Health (HAS) and National Drug Safety (ANSM) agencies recommendations issued in 2014, the French General Direction of Health (DGS) instruction published in November 2021, the French National Blood Bank (EFS) guidelines and the data available in the literature globally define "good transfusion practices" but provide little information about the immuno-hematological and transfusion management of patients who have received an allogeneic hematopoietic stem transplantation (allo-HCT). The aim of this workshop was to harmonize these practices in situations for which there are currently no recommendations. In order to anticipate possible transfusion issues after allo-HCT, we recommend performing, before the transplantation, an extended red blood cell phenotyping of the donor and a detection of HLA alloimmunization in the recipient. We recommend to systematically perform for minor ABO mismatches: a direct antiglobulin test between D8 and D20, and for major ABO mismatches; a titration of anti-A/anti-B antibodies and an erythrocyte chimerism at D100. At one-year post-transplant, we recommend carrying out an erythrocyte chimerism to allow, if necessary, the update of transfusion counselling (RH phenotype, irradiation of packed red blood cells).
Collapse
Affiliation(s)
- Aliénor Xhaard
- AP-HP, hôpital Saint-Louis, service d'hématologie-greffe, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - Muriel Bouton
- EFS Nouvelle-Aquitaine, site de Pessac Haut-Lévêque, avenue de Magellan, Pessac, France
| | - Laurence Delugin
- EFS Bretagne, laboratoire immuno-hématologie érythrocytaire, rue Pierre-Jean-Gineste, 35011 Rennes cedex, France
| | - Christine Giraud
- CHU de Poitiers, service d'hématologie et de thérapie cellulaire, 2, rue de la Miletrie, 86021 Poitiers, France; Centre de soins, EFS NVAQ, site de Poitiers, laboratoire de thérapie cellulaire, 350, avenue Jacques-Cœur, BP 482, 86012 Poitiers cedex, France
| | - Alizée Guyon
- EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France
| | | | - Khadija Hajjout
- Centre régional de transfusion sanguine de Rabat, Rabat, Maroc
| | - Pascal Nicolas
- EFS Grand-Est, 10, rue Spielmann, 67000 Strasbourg, France
| | | | - Vanessa Ratie
- EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France
| | - Anne Boisnard
- AP-HP, hôpital Necker, service d'hématologie adulte, 151, rue de Sèvres, 75015 Paris, France
| | - Lucie Capelle
- CHU de Lille, service hématologie pédiatrique, Lille, France
| | - Sandrine Godin
- CHU de Lille, service hématologie pédiatrique, Lille, France
| | | | - Ibrahim Yacoub-Agha
- Université de Lille, CHU de Lille, Infinite, Inserm U1286, 59000 Lille, France
| | | |
Collapse
|
2
|
Delugin L, Thibert JB, Combet E, Laiguillon G, Peyrard T, Babinet J. Découverte d’un allo-anticorps anti-I1 chez une femme enceinte : bilan et prise en charge. Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Combet E, Nguyen T, Crolle M, Vallaize J, Thibert JB, Delugin L. Anémie hémolytique immunologique associée aux anticorps anti-oxaliplatine. Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Delugin L, Beguet Yachine M, Djobo C, Francois M, Mouchet C, Ratie V, Vincec A, Maenulein E, Thibert JB, Danic B. Suivi des situations de rupture du lien IHE délivrance et conséquences transfusionnelles. Transfus Clin Biol 2018. [DOI: 10.1016/j.tracli.2018.08.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Bertrand G, Leguen A, Delugin L, Renac V. Severe neonatal thrombocytopenia due to fetomaternal anti-A alloimmunization: A case report. Pediatr Neonatol 2018; 59:421-422. [PMID: 29191743 DOI: 10.1016/j.pedneo.2017.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 06/07/2017] [Accepted: 11/10/2017] [Indexed: 10/18/2022] Open
Affiliation(s)
- Gerald Bertrand
- French Blood Services EFS Bretagne, Platelet Immunology Laboratory, Rennes, France.
| | | | - Laurence Delugin
- French Blood Services EFS Bretagne, Immuno-hematology Laboratory, Rennes, France
| | - Virginie Renac
- French Blood Services EFS Bretagne, Platelet Immunology Laboratory, Rennes, France
| |
Collapse
|
6
|
Delugin L, Nimubona S, Leroy MC, Guerout-Verite MA, Thibert JB. Prise en charge d’une allogreffe de cellules souches hématopoïétiques de sang périphérique en situation d’incompatibilité dans le système Kidd. Transfus Clin Biol 2017. [DOI: 10.1016/j.tracli.2017.06.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Krause C, Lauroua P, Andre-Botte C, Auger S, Besiers C, Bouix O, Chartier M, Delamaire M, Delugin L, Giroux-Lathuile C, Mercadier A, Mouchet C, Volle P, Gouvitsos J, Rihet I, Toulemonde E, Djoudi R. Étude comparative multicentrique de cinq automates réalisant les recherches d’anticorps irréguliers (RAI) et les groupes ABO RH.KEL1. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Lauroua P, Krause C, Bouix O, Delamaire M, Delugin L, Mercadier A, Gouvitsos J, Djoudi R. Étude comparative multicentrique du TDA réalisé en technique microplaque QWALYS® versus microfiltration. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Thibert JB, Danic B, Delamaire M, Delugin L, Dugor C, Le Vacon F, Nimubona S, Treussard D, Vasse J, Semana G. Organisation de la prise en charge des besoins transfusionnels des patients atteints d’hémoglobinopathie à l’Établissement français du sang Bretagne. Transfus Clin Biol 2015; 22:5-11. [DOI: 10.1016/j.tracli.2014.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Accepted: 09/06/2014] [Indexed: 12/22/2022]
|
10
|
Thibert JB, Danic B, Delamaire M, Delugin L, Dugor C, Lanfrey A, Lebaudy JP, Tardivel R, Treussard D, Vasse J, Nimubona S, Le Vacon F, Semana G. Organisation de la prise en charge des besoins transfusionnels des patients atteints d’hémoglobinopathie à l’Établissement français du sang Bretagne. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Delamaire M, Delugin L, Dupont I, Semana G. Apport du génotypage érythrocytaire étendu des patients à la sécurité transfusionnelle. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.04.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Delugin L, Delamaire M, Le Maréchal C, Flageul S, Retif S, Semana G. Vérification du typage sérologique RH1 par génotypage. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Le Vacon F, Delugin L, Maniez M. [Study of four kits used for titration of tetanus antibody for selection of plasma donors intended to fractionation]. Transfus Clin Biol 2007; 14:359-68. [PMID: 17466559 DOI: 10.1016/j.tracli.2007.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2006] [Accepted: 03/15/2007] [Indexed: 11/22/2022]
Abstract
UNLABELLED Antitetanus antibodies titration is carried out by French National Blood Services (FNBSs) with the aim of seeking donors whose title of antibodies are greater or equal to 8 IU/ml. Different kits are used: ELISA antitetanus toxoid IgG (The Binding Site), ELISAT (Diagast), tetanus toxoid IgG ELISA (Diamed), ELISA IgG tetanus (Ingen). As the results obtained using these different reagents show some discrepancies with the control results carried out by the Laboratoire Français des Biotechnologies (LFB), it appeared necessary to harmonize the selection practices. With this intention a study of the different kits was initiated. METHOD Different samples were used during this evaluation: (1) the Reference Control (RC) used by the FNBS; (2) a serum sample of high title; (3) a range of dilution of national standard. The following tests were carried out: (1) robustness with the evaluation of the contamination and the board effect; (2) linearity and repeatability (eight deposits of each standard, RC and points of national standard dilutions); (3) reproducibility; (4) homogeneity. After automatic dilution of the samples, the plates were then processed according to the protocol of the manufacturer. RESULTS The study gives the CV in percentage of repeatability and reproducibility, the values of the standards provided as well as the bias compared to the RC and the uncertainty of measurements. CONCLUSION This study gave the possibility to rank each kit compared to RC and to specify the variations which surround each result. This variation can explain the discrepancy of conformity of plasma when title is close to the threshold of selection.
Collapse
Affiliation(s)
- F Le Vacon
- EFS Bretagne, site de Rennes, rue Pierre-Jean-Gineste, 35000 Rennes, France.
| | | | | |
Collapse
|
14
|
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 2001; 132:778-84. [PMID: 11159731 PMCID: PMC1572605 DOI: 10.1038/sj.bjp.0703863] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2000] [Accepted: 11/23/2000] [Indexed: 11/08/2022] Open
Abstract
1. Glibenclamide, a sulphonylurea widely used for the treatment of non-insulin-dependent diabetes mellitus, has been shown to inhibit the activities of various ATP-binding cassette (ABC) transporters. In the present study, its effects towards multidrug resistance protein 1 (MRP1), an ABC efflux pump conferring multidrug resistance and handling organic anions, were investigated. 2. Intracellular accumulation of calcein, an anionic dye substrate for MRP1, was strongly increased by glibenclamide in a dose-dependent manner in MRP1-overexpressing lung tumour GLC4/Sb30 cells through inhibition of MRP1-related calcein efflux. By contrast, glibenclamide did not alter calcein levels in parental control GLC4 cells. Another sulphonylurea, tolbutamide, was however without effect on calcein accumulation in both GLC4/Sb30 and GLC4 cells. 3. Glibenclamide used at 12.5 microM was, moreover, found to strongly enhance the sensitivity of GLC4/Sb30 cells towards vincristine, an anticancer drug handled by MRP1. 4. Efflux of carboxy-2',7'-dichlorofluorescein, an anionic dye handled by the ABC transporter MRP2 sharing numerous substrates with MRP1 and expressed at high levels in liver, was also strongly inhibited by glibenclamide in isolated rat hepatocytes. 5. In summary, glibenclamide reversed MRP1-mediated drug resistance likely through inhibiting MRP1 activity and blocked organic anion efflux from MRP2-expressing hepatocytes. Such effects associated with the known inhibitory properties of glibenclamide towards various others ABC proteins suggest that this sulphonylurea is a general inhibitor of ABC transporters.
Collapse
Affiliation(s)
- Léa Payen
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| | - Laurence Delugin
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| | - Arnaud Courtois
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| | - Yolande Trinquart
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| | - André Guillouzo
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| | - Olivier Fardel
- INSERM U456, Faculté de Pharmacie, 2 Avenue du Pr L. Bernard, 35043 Rennes, France
| |
Collapse
|
15
|
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun 1999; 258:513-8. [PMID: 10329417 DOI: 10.1006/bbrc.1999.0671] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Multidrug resistance-associated protein (MRP) and P-glycoprotein (P-gp) are drug efflux pumps conferring multidrug resistance to tumor cells. RU486, an antiprogestatin drug known to inhibit P-gp function, was examined for its effect on MRP activity in MRP-overexpressing lung tumor GLC4/Sb30 cells. In such cells, the antihormone compound was found to increase intracellular accumulation of calcein, a fluorescent compound transported by MRP, in a dose-dependent manner, through inhibition of cellular export of the dye; in contrast, it did not alter calcein levels in parental GLC4 cells. RU486, when used at 10 microM, a concentration close to plasma concentrations achievable in humans, strongly enhanced the sensitivity of GLC4/Sb30 cells towards two known cytotoxic substrates of MRP, the anticancer drug vincristine and the heavy metal salt potassium antimonyl tartrate. Vincristine accumulation levels were moreover up-regulated in RU486-treated GLC4/Sb30 cells. In addition, such cells were demonstrated to display reduced cellular levels of glutathione which is required for MRP-mediated transport of some anticancer drugs. These findings therefore demonstrate that RU486 can down-modulate MRP-mediated drug resistance, in addition to that linked to P-gp, through inhibition of MRP function.
Collapse
Affiliation(s)
- L Payen
- Unité INSERM U456 Détoxication et Réparation Tissulaire, Faculté des Sciences Pharmaceutiques et Biologiques, 2 Avenue du Pr L. Bernard, Rennes, 35043, France
| | | | | | | | | | | |
Collapse
|